Twist Bioscience and Kyowa Kirin Partner for GPCR Antibody Discovery
25 March 2021 - 11:29PM
Business Wire
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling
customers to succeed through its offering of high-quality synthetic
DNA using its silicon platform, today announced that it signed a
partnership agreement with Kyowa Kirin Pharmaceutical Research,
Inc., a subsidiary of Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE:
4151), a global specialty pharmaceutical company, to discover novel
antibodies for therapeutic use against an undisclosed G
protein-coupled receptor (GPCR) target molecule.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20210325005515/en/
“We are committed to using novel, differentiated technologies to
develop best-in-class therapeutics while expediting the discovery
process,” said Andrew McKnight, President and Chief Scientific
Officer, Kyowa Kirin Pharmaceutical Research, Inc. “We look forward
to a productive and exciting partnership with Twist Bio that will
allow us to discover optimized antibody therapeutics from their
diverse libraries at a rapid pace.”
Under the terms of the agreement, Twist Biopharma, a division of
Twist Bioscience, will leverage its unique “Library of Libraries”
for biologics discovery and its proprietary discovery capabilities
to discover novel GPCR target specific antibodies for Kyowa Kirin.
Twist identifies proprietary antibodies that are precisely designed
to match sequences that occur in the human immune system due to its
unique ability to manufacture DNA at scale. This precise and
rational approach to antibody library creation, combined with
advanced bioinformatics expertise and automation of the early
discovery processes, expedites antibody discovery - decreasing
risk, increasing speed, and lowering the failure rate for antibody
therapeutic development. Using this approach, Twist has also
created target-class focused libraries against difficult to drug
target classes, such as GPCRs; these libraries will be put to use
in the collaboration. Twist received an upfront payment upon
signing and Kyowa Kirin retains an option to obtain development and
commercial rights to any antibodies resulting from the
agreement.
“Kyowa Kirin specializes in leveraging antibody engineering to
develop innovative, life-changing medicines. That expertise
complements Twist’s unique approach to efficient and robust
antibody discovery and optimization,” said Emily M. Leproust,
Ph.D., CEO and co-founder of Twist Bioscience.
About Kyowa Kirin
Kyowa Kirin strives to create and deliver novel medicines with
life-changing value. As a Japan-based Global Specialty
Pharmaceutical Company, we apply cutting-edge science including an
expertise in antibody research and engineering, to address the
needs of patients and society across multiple therapeutic areas
including Nephrology, Oncology, Immunology/Allergy and Neurology.
Across our four regions – Japan, Asia Pacific, North America and
EMEA/International – we focus on our purpose, to make people smile,
and are united by our shared values of commitment to life,
teamwork/Wa, innovation, and integrity. You can learn more about
Kyowa Kirin North America at: https://kkna.kyowakirin.com.
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic
biology and genomics company that has developed a disruptive DNA
synthesis platform to industrialize the engineering of biology. The
core of the platform is a proprietary technology that pioneers a
new method of manufacturing synthetic DNA by “writing” DNA on a
silicon chip. Twist is leveraging its unique technology to
manufacture a broad range of synthetic DNA-based products,
including synthetic genes, tools for next-generation sequencing
(NGS) preparation, and antibody libraries for drug discovery and
development. Twist is also pursuing longer-term opportunities in
digital data storage in DNA and biologics drug discovery. Twist
makes products for use across many industries including healthcare,
industrial chemicals, agriculture and academic research.
Follow us on Twitter | Facebook | LinkedIn | YouTube
Legal Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements. All
statements other than statements of historical facts contained
herein, including without limitation, the ability of the
partnership between Twist and Kyowa Kirin to successfully discover
optimized antibody therapeutics from libraries designed
specifically with sequences that occur naturally in the human body
to prevent immunogenicity and improve pharmacokinetic properties
and for such partnership to expedite antibody discovery, decrease
risk, increase speed and lower the failure rate for antibody
therapeutic development, are forward-looking statements reflecting
the current beliefs and expectations of management made pursuant to
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Such forward-looking statements involve known
and unknown risks, uncertainties, and other important factors that
may cause Twist Bioscience’s actual results, performance, or
achievements to be materially different from any future results,
performance, or achievements expressed or implied by the
forward-looking statements. Such risks and uncertainties include,
among others, the risks and uncertainties of the ability to attract
new customers and retain and grow sales from existing customers;
risks and uncertainties of rapidly changing technologies and
extensive competition in synthetic biology could make the products
Twist Bioscience is developing obsolete or non-competitive;
uncertainties of the retention of a significant customer; risks of
third party claims alleging infringement of patents and proprietary
rights or seeking to invalidate Twist Bioscience’s patents or
proprietary rights; and the risk that Twist Bioscience’s
proprietary rights may be insufficient to protect its technologies.
For a further description of the risks and uncertainties that could
cause actual results to differ from those expressed in these
forward-looking statements, as well as risks relating to Twist
Bioscience’s business in general, see Twist Bioscience’s risk
factors set forth in Twist Bioscience’s Quarterly Report Form 10-Q
filed with the Securities and Exchange Commission on February 9,
2021 and subsequent filings with the SEC. Any forward-looking
statements contained in this press release speak only as of the
date hereof, and Twist Bioscience specifically disclaims any
obligation to update any forward-looking statement, whether as a
result of new information, future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210325005515/en/
Twist Bioscience: Angela Bitting 925-202-6211
abitting@twistbioscience.com
Kyowa Kirin Public Affairs Lauren Walrath 646-526-4454
lauren.walrath.g4@kyowakirin.com
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Jun 2024 to Jul 2024
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Jul 2023 to Jul 2024